Lixte Biotechnology Holdings, Inc. (LIXT)
NASDAQ: LIXT · Real-Time Price · USD
2.440
-0.230 (-8.61%)
Mar 6, 2026, 4:00 PM EST - Market closed
LIXT Employees
Lixte Biotechnology Holdings had 2 employees as of December 31, 2024. The number of employees decreased by 2 or -50.00% compared to the previous year.
Employees
2
Change (1Y)
-2
Growth (1Y)
-50.00%
Revenue / Employee
n/a
Profits / Employee
-$2,066,844
Market Cap
21.26M
Employees Chart
Related Stocks
| Company Name | Employees |
|---|---|
| IO Biotech | 78 |
| Daré Bioscience | 23 |
| Reviva Pharmaceuticals Holdings | 14 |
| Genenta Science | 13 |
| VYNE Therapeutics | 13 |
| NanoViricides | 7 |
| Lexaria Bioscience | 7 |
| Intensity Therapeutics | 7 |
LIXT News
- 17 days ago - LIXTE Biotechnology Appoints Sidney Braun as CEO of its Liora Technologies Europe Ltd. Subsidiary - GlobeNewsWire
- 6 weeks ago - DE LA SOUL-LED “GOOD HEALTH SUMMIT” LAUNCHES FEBRUARY 19 AT MOREHOUSE COLLEGE - GlobeNewsWire
- 6 weeks ago - LIXTE Biotechnology Attending the DealFlow Discovery Conference, January 28-29 - GlobeNewsWire
- 2 months ago - LIXTE and its Collaborators Expand Clear Cell Ovarian Cancer Trial - GlobeNewsWire
- 3 months ago - LIXTE's Strategy Comes Into Focus: Building an Oncology Platform Around Complementary Modalities - Accesswire
- 3 months ago - LIXTE Levels Up From PP2A Innovation to Multi-Modal Oncology - Accesswire
- 3 months ago - LIXTE Steps Into a Key Role in the Rise of Treatment Amplifiers - Accesswire
- 3 months ago - LIXTE Biotechnology Acquires Liora Technologies' Proprietary Proton Therapy Platform for Cancer Treatment - GlobeNewsWire